Latham & Watkins Advises the Underwriters in Veracyte’s Public Offering

A capital markets team advised the underwriters in the genomic diagnostics company’s offering.

August 06, 2020

Veracyte, Inc. has announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of US$30.00 per share. The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Veracyte, are expected to be US$180.0 million. All of the shares are being offered by the Company. In addition, the Company granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. 

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Anthony Gostanian, Denis Griffin and Briana Goncalves.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.